← 返回前沿论文

天然肺趋向性 T(H)9 细胞:对抗已形成的肺转移的利器

英文原题:Natural lung-tropic T(H)9 cells: a sharp weapon for established lung metastases.

PubMed 2024/12/04(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

研究概要

我们的发现强调了T H 9细胞由TRAF6激活驱动的固有肺趋向性,这支持了T H 9细胞作为已形成肺转移的有前景疗法的潜力。

研究思路结论见上方概要

肺转移仍是肿瘤相关死亡的主要原因,治疗选择有限且疗效不理想。在临床前研究中,T辅助9(TH9)细胞已显示出治疗实体瘤的前景。然而,TH9细胞能否应对更具挑战性的情况,例如已形成的肺转移,尚不清楚。此外,全面探索TH9细胞细微的生物学特性,对于进一步揭示其治疗潜力至关重要。

我们分别将T H 1、T H 9和T H 17细胞过继转移至骨肉瘤和三阴性乳腺癌的皮下、原位及已建立肺转移模型中,并在各不同模型内比较其治疗效果。我们采用流式细胞术和体内成像系统评估输血后T H 1、T H 9和T H 17细胞在肺部的积聚模式。我们对体外分化的T H 9细胞进行bulk RNA测序,以阐明趋化因子受体CXCR4,该受体调控其相对于T H 1和T H 17细胞 counterpart 增强的肺趋向性。使用Cd4 cre Cxcr4 flox/flox小鼠,我们研究CXCR4对T H 9细胞肺趋向性的影响。我们进行质谱分析以鉴定负责CXCR4泛素化的E3连接酶,并阐明T H 9细胞环境中调控CXCR4表达的机制。最终,我们分析T H 9细胞输血后的肿瘤免疫组成,并评估辅助抗programmed cell death protein-1 (PD-1)治疗联合T H 9细胞的治疗效果。

在本研究中,我们提供证据表明TH9细胞比TH1和TH17细胞表现出更高的肺趋向性,从而在对抗已形成的肺转移方面表现出卓越的疗效。CXCR4-CXCL12轴负责TH9细胞的肺趋向性,因为在CD4+ T细胞中敲除CXCR4会逆转其肺部积聚。机制上,肿瘤坏死因子受体相关因子6(TRAF6)驱动的TH9细胞中NF-κB信号过度激活抑制了ITCH介导的CXCR4泛素化,导致CXCR4积累增加并增强TH9细胞的肺趋向性。此外,TH9细胞输注显著改善了免疫抑制微环境。TH9细胞和抗PD-1在肿瘤控制中表现出协同效应。

展开英文摘要原文

BACKGROUND: Lung metastasis remains the primary cause of tumor-related mortality, with limited treatment options and unsatisfactory efficacy. In preclinical studies, T helper 9 (T H 9) cells have shown promise in treating solid tumors. However, it is unclear whether T H 9 cells can tackle more challenging situations, such as established lung metastases. Moreover, comprehensive exploration into the nuanced biological attributes of T H 9 cells is imperative to further unravel their therapeutic potential. METHODS: We adoptively transferred T H 1, T H 9, and T H 17 cells into subcutaneous, in situ , and established lung metastases models of osteosarcoma and triple-negative breast cancer, respectively, comparing their therapeutic efficacy within each distinct model. We employed flow cytometry and an in vivo imaging system to evaluate the accumulation patterns of T H 1, T H 9, and T H 17 cells in the lungs after transfusion. We conducted bulk RNA sequencing on in vitro differentiated T H 9 cells to elucidate the chemokine receptor CXCR4, which governs their heightened pulmonary tropism relative to T H 1 and T H 17 cell counterparts. Using Cd4 cre Cxcr4 flox/flox mice, we investigate the effects of CXCR4 on the lung tropism of T H 9 cells. We performed mass spectrometry to identify the E3 ligase responsible for CXCR4 ubiquitination and elucidated the mechanism governing CXCR4 expression within T H 9 cellular milieu. Ultimately, we analyzed the tumor immune composition after T H 9 cell transfusion and evaluated the therapeutic efficacy of adjunctive anti-programmed cell death protein-1 (PD-1) therapy in conjunction with T H 9 cells. RESULTS: In this study, we provide evidence that T H 9 cells exhibit higher lung tropism than T H 1 and T H 17 cells, thereby exhibiting exceptional efficacy in combating established lung metastases. CXCR4-CXCL12 axis is responsible for lung tropism of T H 9 cells as ablating CXCR4 in CD4 + T cells reverses their lung accumulation. Mechanistically, tumor necrosis factor receptor-associated factor 6 (TRAF6)-driven hyperactivation of NF-κB signaling in T H 9 cells inhibited ITCH-mediated ubiquitination of CXCR4, resulting in increased CXCR4 accumulation and enhanced lung tropism of T H 9 cells. Besides, T H 9 cells' transfusion significantly improved the immunosuppressed microenvironment. T H 9 cells and anti-PD-1 exhibit synergistic effects in tumor control. CONCLUSIONS: Our findings emphasized the innate lung tropism of T H 9 cells driven by the activation of TRAF6, which supports the potential of T H 9 cells as a promising therapy for established lung metastases.

论文信息

作者
Chen T、Qiao C、Yinwang E、Wang S、Wen X、Feng Y、Jin X、Li S
第一作者单位
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.China
通讯作者单位
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China linnong@zju.edu.cn yezhaoming@zju.edu.cn caizj@zju.edu.cn libinghao@zju.edu.cn.China
期刊
Journal for immunotherapy of cancer2024 Dec 4
原文标识
PubMed 39631847 · DOI 10.1136/jitc-2024-009629